MDXGMDXGHealthcare · Biotechnology

MDXG Stock Forecast: MiMedx Group, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$3.19
+0.16% on the day

The 5 Wall Street analysts covering MiMedx Group, Inc. hold a median 12-month price target of $7 — +119.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 17 Nov 2026 — in the upper half.

Market cap
$464.0M
Ticker Nerd rank
69/ 100
Median analyst target
$7.00
Analysts covering
5
Revenue$64.4M−34.7% y/y
Operating income−$18.5M
Net income−$14.8M
Free cash flow−$10.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.1%
1M
−28.1%
YTD
−53.0%
1Y
−52.6%
From 52W high
−56.1%
From 52W low
+3.1%
$3.09
$7.25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MDXG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MiMedx Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
69/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Issuance
89
Value
82
Volatility
77
Quality
69
Size
52
Momentum
33
Revisions
29
Growth
23

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MDXG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDXG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26MDXGHigh $8.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $6.00Median $7.00High $8.00

The green dot is the last close — the median target sits +119.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Nov 2026Cantor FitzgeraldReiteratesOverweight$8.00
27 Aug 2026Craig-HallumMaintainsBuy$6.00 → $8.00
17 Aug 2026Cantor FitzgeraldReiteratesOverweight$8.00
17 Aug 2026Cantor FitzgeraldReiteratesOverweight—
30 Apr 2026CitizensMaintainsMarket Outperform—
30 Apr 2026CitizensMaintainsMarket Outperform$7.00 → $6.00
20 Apr 2026CitizensMaintainsMarket Outperform—
17 Apr 2026Craig-HallumMaintainsBuy—
23 Feb 2026CitizensInitiatesMarket Outperform—
17 Feb 2026Cantor FitzgeraldMaintainsOverweight—
20 Jan 2026Lake StreetMaintainsBuy—
17 Dec 2025MizuhoMaintainsOutperform—
31 July 2025Cantor FitzgeraldMaintainsOverweight—
15 July 2025Cantor FitzgeraldReiteratesOverweight—
27 Feb 2025Cantor FitzgeraldReiteratesOverweight—
1 Aug 2024Cantor FitzgeraldReiteratesOverweight—
1 Aug 2024Craig-HallumMaintainsBuy—
2 July 2024Cantor FitzgeraldInitiatesOverweight—
1 May 2024HC Wainwright & Co.ReiteratesBuy—
7 Mar 2024Lake StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MDXG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MDXG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, MiMedx Group, Inc. returned −52.6% against +12.2% for the S&P 500, dividends included.

MDXG vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26MDXGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MDXG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

MiMedx Group, Inc. (MDXG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
97.5×

Cheaper than 7% of US stocks

Price / sales
1.5×

Cheaper than 56% of US stocks

Price / book
2.2×

Cheaper than 38% of US stocks

EV / EBITDA
−19.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
−45.2%

Higher than 6% of US stocks

Earnings growth (YoY)
−34.7%

Higher than 15% of US stocks

Gross margin
69.0%

Higher than 82% of US stocks

Operating margin
−8.3%

Higher than 25% of US stocks

Net margin
−6.3%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−8.5%

Higher than 37% of US stocks

Return on assets
−5.4%

Higher than 31% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MiMedx Group, Inc. (MDXG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MiMedx Group, Inc. has a market value of $464.0M and an enterprise value of $343.3M.

  • Revenue in the twelve months to 30 June 2026: $355.2M. The latest quarter shrank 45.2% year on year.

  • Net income over the same four quarters: $6.2M, a 1.8% net margin.

  • Diluted earnings per share, trailing twelve months: $0.04.

  • Free cash flow in the twelve months to 30 June 2026: $44.4M.

  • MiMedx Group, Inc. spent $14.6M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 145.7M.

  • Trailing P/E: 97.5×; forward P/E: 127.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • MiMedx Group, Inc. employs 808 people — $440K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

MDXG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MDXGMiMedx Group, Inc.$464.0M69
RGNXREGENXBIO, Inc.$472.8M63
NGNENeurogene, Inc.$478.2M39
BLSMBlossomhill Therapeutics, Inc.$463.6M1
FENCFennec Pharmaceuticals, Inc.$463.6M95
OCSOculis Holding AG$463.6M27
MNPRMonopar Therapeutics, Inc.$481.6M61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MiMedx Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDXG news & analysis

MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles

MarketBeat · 16 Nov 2026negative

MiMedx CFO Doug Rice said at a conference that the company is relying on growth in its surgical business and its pending Sanara MedTech acquisition to help offset a difficult year for its wound care franchise.

Why it matters — The comments highlight how MiMedx expects surgery growth and the pending deal to address challenges in wound care.

MIMEDX to Participate in Upcoming Investor Conferences

GlobeNewsWire · 6 Nov 2026neutral

MiMedx Group announced that members of its senior management will participate in upcoming investor conferences.

Why it matters — The announcement informs MDXG watchers about planned opportunities to hear from the company’s senior management.

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MarketBeat · 29 Oct 2026negative

MiMedx reported third-quarter net sales of $62 million, down 45% year over year, as a 71% decline in wound care revenue offset 9% growth in surgical revenue.

Why it matters — The results show how disruption in the wound care market and growth in surgical business affected MiMedx's sales mix and overall revenue.

MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript

Seeking Alpha · 28 Oct 2026neutral

Seeking Alpha published a transcript of MiMedx Group, Inc.’s Q3 2026 earnings call. The excerpt provides no further details about the discussion.

Why it matters — The transcript is a source for MDXG watchers seeking information from the company’s quarterly earnings call, but the supplied excerpt does not describe its contents.

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

GlobeNewsWire · 28 Oct 2026positive

MiMedx announced its third-quarter 2026 operating and financial results, reporting continued double-digit year-over-year surgical franchise volume growth and wound care center volume growth both sequentially and year over year. It also reported a favorable federal court ruling in the AXIOFILL regulatory classification matter and announced a patent license agreement.

Why it matters — MDXG watchers may note the reported volume growth and legal and intellectual-property developments alongside the quarterly results.

FAQ

Frequently asked questions about MDXG stock

What is the MDXG stock price forecast for 2026-2027?

The 5 Wall Street analysts covering MiMedx Group, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDXG stock a buy right now?

Of the 5 analysts covering MiMedx Group, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MiMedx Group, Inc. 69 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDXG?

As at 17 Nov 2026, MiMedx Group, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will MDXG stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +119.8% from the last close, and Ticker Nerd's factor model ranks MiMedx Group, Inc. 69 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDXG stock forecast for 2030?

No analyst covering MiMedx Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.

How has MDXG stock performed over the past year?

MiMedx Group, Inc. returned -52.6% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MiMedx Group, Inc. do?

MiMedx Group, Inc. is a healthcare company focused on regenerative biologics and advanced wound care products.

What is the latest news on MDXG?

The most recent item we track (MarketBeat, 16 Nov 2026): "MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles". MiMedx CFO Doug Rice said at a conference that the company is relying on growth in its surgical business and its pending Sanara MedTech acquisition to help offset a difficult year for its wound care franchise.

Company

About MiMedx Group, Inc.

MiMedx Group, Inc. is a healthcare company focused on regenerative biologics and advanced wound care products. MiMedx Group, Inc. develops, manufactures, and markets placental tissue allografts and other biomaterial products used in wound care, surgical, burn, orthopedic, spine, sports medicine, ophthalmic, and dental applications. Its portfolio includes products derived from human placental and umbilical cord tissues, designed to support tissue repair and biologic healing in clinical settings. The company serves hospitals, physicians, and other healthcare providers through a range of wound management and surgical solutions. MiMedx Group, Inc. operates as a specialized player in the broader regenerative medicine market, with products that are used across multiple therapeutic areas where biologic tissue processing and advanced treatment options are important.

CEO Mr. Joseph H. Capper · 808 employees · United States · https://www.mimedx.com